An Open Label Extension Study in Subjects With Fragile X Syndrome

NCT01555333 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
357
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Seaside Therapeutics, Inc.